Page 8 - Flipbook

MIBC

• High risk of recurrence (~50%), progression to metastatic disease

• Standard of care recommendation by ALL guidelines:

‒ Cisplatin-based neoadjuvant chemotherapy

• Pathological complete response (pCR) linked to improved OS

• But in some series up to 50% are deemed “cisplatin-ineligible”